Victoria P. Werth - Concepedia

Author

Victoria P. Werth

Also Known As

Borradori, Luca, Costner, Melissa, Dick, Sarah, Louis Flaspohler, Matteo Bottai, Rohit Aggarwal, V P Werth, V Werth, V. P. Werth, V. Werth

791

Publications

30.2K

Citations

H-Index

152

Concepts

All Affiliations

University of Pennsylvania Philadelphia VA Medical Center Hospital of the University of Pennsylvania Brigham and Women's Hospital New York University

About

Victoria P. Werth is an author at University of Pennsylvania specializing in medicine, dermatology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	92	5.9K
2	Health Sciences	4	4	147
3	Engineering	2	2	60
4	Education	1	1	14
5	Natural Sciences	1	1	26

Victoria P. Werth

220

Publications

21.7K

Citations

H-Index

Page 1

	Year	Citations
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus Michelle Petri, Ana‐Maria Orbai, Graciela S. Alarcón, Arthritis & Rheumatism	2012	5.1K
2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups Ingrid E. Lundberg, Anna Tjärnlund, Matteo Bottai, Annals of the Rheumatic Diseases	2017	1.4K
Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus Richard Furie, Munther A. Khamashta, Joan T. Merrill, Arthritis & Rheumatology	2016	829
2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups Ingrid E. Lundberg, Anna Tjärnlund, Matteo Bottai, Arthritis & Rheumatology	2017	678
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus Dédée F. Murrell, Sarah Dick, A. R. Ahmed, Journal of the American Academy of Dermatology PathogenesisImmunologyTherapeutic ResponseEnd PointsConsensus Statement	2008	575
Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study Munther A. Khamashta, Joan T. Merrill, Victoria P. Werth, Annals of the Rheumatic Diseases	2016	488
The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An Outcome Instrument for Cutaneous Lupus Erythematosus Joerg Albrecht, Lynne Taylor, Jesse A. Berlin, Journal of Investigative Dermatology Autoimmune DiseaseSystemic Lupus Erythematosus TreatmentLupusClinical DermatologyOutcome Instrument	2005	487
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts Dédée F. Murrell, Benjamin S. Daniel, P. Joly, Journal of the American Academy of Dermatology Bullous PemphigoidPublic HealthInternational PanelOutcome MeasuresEpidemiology	2011	365
Diagnosis and management of pemphigus: Recommendations of an international panel of experts Dédée F. Murrell, S.M. Peña, P. Joly, Journal of the American Academy of Dermatology MedicineDermatologyPathologyInternational Panel	2018	356
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study Ronald van Vollenhoven, Bevra H. Hahn, George C. Tsokos, The Lancet RheumatologyIl-23 InhibitorAutoimmune DiseaseSclerodermaSystemic Lupus Erythematosus Treatment	2018	317

Page 1